p53 Loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis

Cancer Genetics and Cytogenetics

Volumn 98, Issue 1, 1997, Pages 28-35

  Stuppia, Liborio ^b   Calabrese, Giuseppe ^a   Peila, Rita ^b   Guanciali Franchi, Paolo ^a   Morizio, Elisena ^a   Spadano, Antonio ^c   Palka, Giandomenico ^a,d  

^a UNIVERSITY OF CHIETI   (Italy)

^b CNR   (Italy)

^c Ospedale Civile di Pescara   (Italy)

^d NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSFERASE;

ADULT; AGED; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIAGNOSIS; DISEASE COURSE; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR CLONING; POINT MUTATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; APOPTOSIS; BLAST CRISIS; DNA FRAGMENTATION; FEMALE; GENE DELETION; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; POINT MUTATION; TREATMENT OUTCOME;

LOA;

EID: 0030817094     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(96)00413-X     Document Type: Article

References (32)

1. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld J (1984): Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985): Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315:550-554.
3. Kabarowski JHS, Allen PB, Wiedemann LM (1994): A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR/ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 13:5887-5895.
4. Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V (1989): Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74:2318-2324.
5. Mashal R, Shaltrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujllo J, Gutterman J, Deisseroth A (1990): Rearrangements and expression of p53 in the chronic phase and blast crisis of Chronic Myelogenous Leukemia. Blood 75:180-189.
6. Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A, Canaani E (1991): p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88:6293-6297.
7. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishiraki K (1992): Frequent p53 gene mutations in blastic crisis of Chronic Myelogenous Leukemia, especially in myeloid crisis harboring loss of chromosome 17p. Cancer Res 52:6588-6593.
8. Nakai H, Misawa S, Horiike S, Maekawa T, Kashima K, Ishizaki K (1995): Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukemia. Br J Haematol 90:147-155.
9. Sandberg AA (1990): The Chromosomes in Human Cancer and Leukemia. Elsevier North Holland, New York, pp. 465-474.
10. Cervantes F, Rozman M, Rosell J, Urbano-Ispizua A, Monsterrat E, Rozman C (1990): A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukemia. Br J Haematol 76:27-32.
11. McBride OW, Merry D, Givol D (1986): The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83:130-134.
12. Isobe M, Emanuel BS, Givol D, Oren M, Croce C (1986): Localization of gene for human p53 tumor antigen to band 17p13. Nature 320:84-85.
13. Levine AJ, Momand J, Finlay CA (1991): The p53 tumor suppressor gene. Nature 351:453-446.
14. Symonds H, Krall L, Remington L, Saenz-Robbles M, Lowe S, Jacks T, van Dick T (1994): p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711.
15. Wyllie AH, (1993): Apoptosis. Br J Cancer 67:205-208.
16. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991): Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345-347.
17. Zhu YM, Bradbury D, Russell N (1993): Expression of different conformations of p53 in blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br J Cancer 68:851-855.
18. Pinkel D, Straume T, Gray VW (1986): Cytogenetic analysis using quantitative high-resolution fluorescence hybridization. Proc Natl Acad Sci USA 83:2934-2933.
19. Calabrese G, Sallese M, Stornaiuolo A, Stuppia L, Palka G, De Blasi A (1994): Chromosome mapping of the human arrestin (SAG), β-arrestin 2 (ARRB2), and β-adrenergic receptor kinase 2 (ADRBK2) genes. Genomics 23:2813-288.
20. Dunham I, Lengauer C, Cremer T, Featherstone T (1992): Rapid generation of chromosome-specific alphoid DNA probes using the polymerase chain reaction. Hum Genet 88:457-462.
21. Van Roy N, Laureys G, Versteeg R, Opdenakker G, Speleman F (1993): High resolution fluorescence mapping of 46 markers to the short arm of human chromosome 1. Genomics 11:73-78.
22. Stuppia L, Calabrese G, Guanciali Franchi P, Di Bartolomeo P, Antonucci A, Peila R, Torlontano G, Palka G (1993): Detection of minimal residual disease by polymerase chain reaction in patients with different hematologic diseases treated by bone marrow transplantation. Cancer Genet Cytogenet 65:88-92.
23. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SM, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989): Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708.
24. Kanjal S, Pierceall WE, Cummings KK, Krupke M, Ananthaswamy HN (1993): High frequency of p53 mutations in ultraviolet radiation-induced murine skin tumors: evidence for strand bias and tumor heterogeneity. Cancer Res 53:2961-2964.
25. Sgonc R, Boeck G, Dietrich H, Gruber J, Recheis H, Wick G (1994): Simultaneous determination of cell surface antigens and apoptosis. Trends In Genetics 10:41-42.
26. Stuppia L, Cinti C, Santi S, Peila R, Calabrese G, Palka G, Maraldi NM, Sumner AT (1995): Comparison of methods for the detection of in situ restriction enzyme-nick translation using fluorochromes and confocal microscopy. Genome 38: 1032-1036.
27. Kantarjian HM, Smith TL, Mc Credie KB, Keating MJ, Walters RS, Talpaz M, Mester JP, Bligham G, Gehan E, Freireich EJ (1985): Chronic Myelogenous Leukemia: A mullivariale analysis of the associations of patient characteristics and therapy with survival. Blood 66:1326-1335.
28. Sales V, Rojo J, Collazo J, Lagunas E, Aguilar E, Albisua L (1991): Chronic granulocytic leukemia in blast crisis: Prognostic factors. In Vivo 5:281-286.
29. Nakai H, Misawa S, Taniwaki M, Horiike S, Takashima T, Seriu T, Nakagawa H, Fujii H, Shimazaki C, Maruo N, Akaogi T, Uike N, Abe T, Kashima K (1994): Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blastic crisis of chronic myelogenous leukemia. Br J Haematol 87:425-427.
30. Osman Y, Moriyama Y, Shibata A (1995): Enhanced elimination of Ph+ chromosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-alpha, TNF, and quercetin): Its application to autologous bone marrow transplantation for CML. Exp Hematol 23:444-452.
31. Anad S, Verma H, Kumar L, Singh N (1993): Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin. Cancer Lett 88:101-105.
32. Mori N, Wada M, Yokota J, Terada M, Okada M, Teramura M, Masuda M, Hoshino S, Motoji T, Oshimi K, Mizoguchi H (1992): Mutations of the p53 tumor suppressor gene in hematologic neoplasms. Br J Haematol 81:235-240.